21 July 2025
21 July 2025
The acquisition includes Ayvakit/Ayvakyt, a treatment for rare immunological diseases.
The negative vote for Blenrep comes just days before the 23 July PDUFA date.
EURneffy is the first needle-free emergency treatment for anaphylaxis available in the UK.
The joint effort will focus on providing patients with medication guidance, reminders, tracking of efficacy and health education.
As one FDA initiative works to sustain the momentum of rare disease research, other events threaten to slow progress.
There has been a rise in deals and investment to grow US manufacturing operations, due to impending tariffs on the sector.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
